1 / 15

Continuous Treatment Data Collection in Finland

Martta Forsell, the Finnish Focal Point, coordinates data collection for drug-related treatment in Finland. The voluntary program involves separate client questionnaires not integrated into electronic records. Data collected from 85 units and 2,688 clients in 2012 exhibit no apparent biases. Ongoing improvements include a revised questionnaire for better data quality and coverage, particularly in defining primary drug on continuous treatment. The primary drug is determined based on recent or historical drug use, emphasizing addiction for clients in OST programs. Continuous treatment monitoring is carried out through specific questionnaires for in-patient and out-patient facilities. The focus remains on enhancing the overall understanding and reporting of treatment inputs and epidemiology.

najila
Download Presentation

Continuous Treatment Data Collection in Finland

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Continuous treatment in Finland Martta Forsell, the Finnish Focal Point Martta Forsell

  2. Data collection in Finland • Voluntary for the treatment centers • Separate client questionnaire, not (yet) part of electronic patient record. • When entering treatment • If client continues in treatment, new questionnaire in January (or springtime..) • Covers an estimated one third of the drug-related treatment • In 2012, 85 units providing drug-related treatment participated in the information collecting, submitting data on 2,688 clients. • No obvious biases Esityksen nimi / Tekijä

  3. Finnish National Treatment Data 2012(n= 2 688) Martta Forsell

  4. Finnish National Treatment Data 2012 (n= 2 688) Esityksen nimi / Tekijä

  5. Finnish National Treatment Data 2012 Esityksen nimi / Tekijä

  6. Length of the treatment (in years since start of treatment) on continuous treatment Esityksen nimi / Tekijä

  7. Length of the treatment as ‘episodes’ (columns) and the OST for clients (black) Esityksen nimi / Tekijä

  8. Renewed questionnaire 2014 onwards The Finnish survey and guidelines needed improving + TDI 3.0 • The questionnaire has been revised 2012-2013 and fully renewed questionnaire will be implemented 2014. • Will be 100% TDI 3.0 compatible • Rethinking on (among others) • ‘primary drug’ on continuous treatment • Continuous treatment in an in-patient facility • OST information • More ‘re-launch’ than ‘fine-tuning’. Overall aims: • better data quality • better coverage • better understanding of the coverage Esityksen nimi / Tekijä

  9. Primarydrug • Defining the primary drug at the start of treatment is straight forward enough • But on continuous treatment the primary problem can change Esityksen nimi / Tekijä

  10. Primarydrug? THEN NOW Primarydrug? Secondarydrug? Route of admistration? Frequency? Intrest on treatmentinputs Intrest on epidemiology Esityksen nimi / Tekijä

  11. PrimarydrugSecondarydrug- route-frequency THEN NOW • Primary & secondarydrug • Route • Frequency Esityksen nimi / Tekijä

  12. Primary (secondary) drug in Finland from 2014 onwards • Primary drug now (~30 days prior entering treatment) OR • Long-standing problem drug which • contributed to the entering treatment or • is emphasized in the current treatment ~ drug the client is addicted to (whether at the moment active drug use) • The OST clients are always addicted > opioid as long-standing drug • Frequency is always the very last 30 days (except in-patient..) Esityksen nimi / Tekijä

  13. In-patientclient • Enterstreatment 1.Dec • Questionnaire: use of drugs in Nov • New questionnaire in Jan: use of drugs in Nov • > the copy of previousquestionnaire • Client checks out in Feb • New questionnairein Feb in an out-patientfacility: useof drugs in Jan-Feb Esityksen nimi / Tekijä

  14. Primary (secondary) drug in Finland from 2014 onwards • Primary drug now (~30 days prior entering treatment) OR • Long-standing problem drug which • contributed to the entering treatment or • is emphasized in the current treatment ~ drug the client is addicted to (whether at the moment active drug use) • The OST clients are always addicted > opioid as long-standing drug • Frequency is always the very last 30 days (except in-patient..) • NO more in-patient continuous questionnaire Esityksen nimi / Tekijä

  15. Primary (secondary) drug in Finland from 2014 onwards • Primary drug now (~30 days prior entering treatment) OR • Long-standing problem drug which • contributed to the entering treatment or • is emphasized in the current treatment ~ drug the client is addicted to (whether in remiss or not) • Which we should put forward as we report the primary drug for the EMCDDA? Esityksen nimi / Tekijä

More Related